Navigation Links
New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings

PRINCETON, N.J.--(BUSINESS WIRE)--Mar 26, 2007 - Cytogen Corporation (NASDAQ: CYTO) today announced that five abstracts will be presented or published at upcoming major medical meetings. The data will include various Phase 1 clinical results for QUADRAMET(R) (samarium Sm-153 lexidronam injection) in combination settings for the treatment of metastatic bone disease arising from prostate cancer and multiple myeloma, as well as data from a study evaluating the outcomes of prostate cancer patients based on the findings of PROSTASCINT(R) (capromab pendetide) imaging. These presentations underscore Cytogen's strategy to maximize the market potential of its approved products through data-driven initiatives.

New data from three separate Phase 1 studies of QUADRAMET in combination with docetaxel (Taxotere(R), Sanofi-Aventis) in patients with hormone-refractory prostate cancer have been accepted for publication and/or presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place June 1-5, 2007, in Chicago, Illinois. The primary objective of each of these Phase 1 studies is to determine the safety and tolerability of the combination regimens utilizing a variety of doses and dosing regimens.

Additionally, new and complete data from a Phase 1 study evaluating QUADRAMET in combination with bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) in patients with relapsed multiple myeloma will be presented in an oral presentation at the XIth International Myeloma Workshop taking place June 25-30, 2007 in Greece. The primary objective of the Phase 1 study was to determine the safety and tolerability of the combination regimen. As a secondary objective, the study also assessed response rates.

Today, Cytogen also reported that new data from an outcomes study in prostate cancer patients whose PROSTASCINT images showed uptake in the central abdomen as compared to those with
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
(Date:8/29/2014)... , Aug. 29, 2014  Pacific Medical Data ... new website design . The main website, along ... showcases the company,s new services and content relevant to ... a new streamlined design, viewers can now better understand ... health care practices and create a more visible platform ...
(Date:8/29/2014)... Research and Markets  has announced the addition of ... 2014-2018" report to their offering. ... connect, support, or surround bones. There are several types ... fascia, and other fibrous tissues. Repetitive use, accidents, injuries, ... in wear and tear in these tissues. Orthopedic soft ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3PMDS Announces New Website 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
(Date:8/31/2014)... 2014 NutriGold announces that its ... organic fruits and berries, has been approved ... tested, including purity and label claims. , ... Acid from genetically modified and chemically produced corn ... process involves the use of a genetically modified ...
(Date:8/31/2014)... 2014 Market Research Report on ... is a professional and in-depth market survey on ... report firstly reviews the basic information of Cell ... technology. , The report then explores global and ... their product specification, capacity, production value, and market ...
(Date:8/31/2014)... finds that invisible blood in urine may be an early ... for clinicians. , Scientists at the University of Exeter ... age of 60 who had invisible blood in their urine ... bladder cancer. The figure was around half those who had ... of bladder cancer. However, it was still higher than figures ...
(Date:8/31/2014)... August 31, 2014 Adults in the U.S. ... insurance coverage can now use the Quotes Pros website as ... this year can help consumers to find and compare costs ... use of the search tool this year is expected to ... different coverage plans at various price points. The strength of ...
(Date:8/31/2014)... 2014 According to an article posted in ... Times Stronger than Heroin , a new opiate has begun ... more potent than heroin. Known as acetyl fentanyl, this opiate ... many overdoses and emergency room visits among opiate addicts because ... individual might demonstrate the signs of a heroin overdose, they ...
Breaking Medicine News(10 mins):Health News:NutriGold’s Organic Wholefood-Sourced Vitamin C Gets ConsumerLab’s Seal of Approval 2Health News:NutriGold’s Organic Wholefood-Sourced Vitamin C Gets ConsumerLab’s Seal of Approval 3Health News:Cell Harvesting System Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Cell Harvesting System Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Cell Harvesting System Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Invisible blood in urine may indicate bladder cancer 2Health News:Life Insurance Quotes Tool Installed for Public Use at New Insurer Portal Website 2Health News:New Street Drug Found to be Much More Powerful Than Heroin 2Health News:New Street Drug Found to be Much More Powerful Than Heroin 3
... Brompton and Harefield NHS Trust,s Leadership Role in the Treatment ... ... Stereotaxis, Inc. (Nasdaq:,STXS) announced that British Prime Minister Gordon Brown presided ... lab at,Royal Brompton Hospital in London. The new lab features Stereotaxis ...
... Federal Rule Changes ... Tools, CHICAGO, June 24 Allscripts, the ... physicians use,to improve healthcare, announced today that it ... Hospital Presbyterian in Newport Beach,Calif. preferred pricing on ...
... Go Healthy, Inc. (Pink,Sheets: GOHE) announced today that ... based in Myakka, Florida. Under the terms of,the agreement, ... marketing and,sales related services designed to bring awareness of ... specifics outlined in the agreement,are as follows:, -- ...
... on Top Industry ... Challenges, LAS ... change, healthcare chief financial officers feel the need to,anticipate change and begin ... CFOs face daunting challenges,and their insights on the state of the industry ...
... SARASOTA, Fla., June 24 The following statement was,issued today ... no convincing evidence that early screening,detection, and treatment improve ... include potential adverse health ... and treatment side effects." Policy Statement from ...
... the open-access journal PLoS Neglected Tropical Diseases ... Asia, and Latin America are also occurring frequently among ... and children. These diseases the "neglected infections ... parasitic, bacterial, and congenital infections. , While most ...
Cached Medicine News:Health News:London's Royal Brompton Hospital Opens New Electrophysiology Lab With State of the Art Magnetic Technology to Treat Arrhythmias 2Health News:London's Royal Brompton Hospital Opens New Electrophysiology Lab With State of the Art Magnetic Technology to Treat Arrhythmias 3Health News:Hoag Memorial Hospital Presbyterian Selects Allscripts for Electronic Health Record Subsidy Program 2Health News:Hoag Memorial Hospital Presbyterian Selects Allscripts for Electronic Health Record Subsidy Program 3Health News:Go Healthy Signs Marketing Contract with AIM Marketing 2Health News:Intersection of Financial and Regulatory Forces is Broadening Roles of Healthcare CFOs 2Health News:Intersection of Financial and Regulatory Forces is Broadening Roles of Healthcare CFOs 3Health News:Diagnostic Center for Disease: Robotic Prostatectomy - A Race to Failure? 2Health News:Diagnostic Center for Disease: Robotic Prostatectomy - A Race to Failure? 3Health News:Diagnostic Center for Disease: Robotic Prostatectomy - A Race to Failure? 4Health News:'Neglected infections of poverty' in US disable hundreds of thousands of Americans annually 2
Supplied sterile in peel-open packages. Intended for one-time use....
Used for percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
Used for percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
... Olympuss extensive line of affordable, high-quality ... our high-performance light sources to provide optimal ... light weight and durable design give you ... effectively and efficiently. And each is fully-autoclavable ...
Medicine Products: